SCHEMBL12808039

SCHEMBL12808039

Cc1cc(O)c(C(=O)CCc2ccc3occc3c2)c(OC2OC(CO)C(F)C(O)C2O)c1

nearest known ligand 0.86

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 15/20 0.86
▸ SLC5A2 P31639 13/20 0.86
▸ SLC28A3 Q9HAS3 2/20 0.54
▸ HPGD P15428 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ SLC28A2 O43868 1/20 0.53
▸ EPHX2 P34913 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30268946 0.93 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL14104531 0.93 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL7581216 0.93 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL6725644 0.93 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL14080086 0.89 SLC5A1 (0.89) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL16854936 0.87 SLC5A1 (0.86) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808046 0.87 SLC5A1 (0.70) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL7582193 0.87 SLC5A1 (0.80) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL13953727 0.87 SLC5A1 (0.83) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808059 0.86 SLC28A3 (0.71) SLC5A1SLC5A2SLC28A3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 — — US disclosed
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 — — US disclosed
WO-2011039338-A2 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES SANOFI-AVENTIS (FR) 2011-04-07 — — WO disclosed
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-05-08 — — US disclosed
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-05-08 — — US disclosed
US-7288528-B2 Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-30 — — US disclosed
US-7288528-B2 Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SLC5A2, SLC5A1, UGGT1 SLC5A1 2/4885SLC5A2 1/4885SLC28A3 1031/4885
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SLC5A1, SLC5A2, SOST SLC5A1 1/4885SLC5A2 2/4885SLC28A3 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback